RSV-targeting antibodies

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind Respiratory Syncytial Virus (RSV) with improved efficiency and / or improved neutralization activity. Also disclosed are pharmaceutical compositions comprising such antibodies and fragments, and methods of preventing or treating RSV infection or RSV disease in a subject using the same.

Description

RSV- TARGETING ANTIBODIESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 700,421, filed on September 27, 2024, which is incorporated by reference herein in its entirety.REFERENCE TO SEQUENCE LISTING

[0002] This application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on September 24, 2025, is named OMS-00125_SL.xml and is 2,396,056 bytes in size.FIELD

[0003] This application relates to certain anti-RSV antibodies, antigen-binding fragments thereof, pharmaceutical compositions comprising such antibodies and fragments, and methods and uses relating to the same, including uses for prevention and treatment of RSV infection or disease.BACKGROUND

[0004] Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. RSV is a highly contagious virus that is a common cause of infections of the upper airways and lungs. RSV is an important cause of morbidity and mortality in infants and young children (Ananworanich et al., 2021, Vaccines (Basel) 9(9)). Estimates suggest that globally in 2019, 6.6 million RSV infections occurred in infants 26 days to 6 months of age, resulting in 1.4 million hospital admissions and 45,700 RSV-attributable deaths. RSV is estimated to be the cause 3.6% of deaths in children aged 0 to 6 months.

[0005] RSV is also an important cause of severe respiratory disease in adults aged >65 years, causing an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually in the United States (Melgar et al., 2023, MMWR Morb Mortal Wkly Rep. 72(29):793-801). In adults and children undergoing hematopoietic stem cell transplantation, who experience high levels of immunosuppression, RSV infection has a case fatality rate of ~6% (Ricco et al., 2024,Infect Dis Rep. 16(2):317-55). No anti-RSV antibody has been approved by the FDA for treatment of these patients.

[0006] Improved antibodies and therapies for prevention and / or treatment of RSV infection are needed.BRIEF SUMMARY OF THE INVENTION

[0007] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91, or an amino acid sequence that differs from SEQ ID NO: 91 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): E30Q, E30G, D31G, 133 V, I34V, and N35S, in any combination;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105, or an amino acid sequence that differs from SEQ ID NO: 105 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): 15 IM, I52V, L55F, T57A, H59Y, G61A, P62S, G66A, and G66R, in any combination; and(iii) a heavy chain contact region 3 comprising ATETALVVTGTYFLHYFDN (SEQ ID NO: 135); and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the heavy chain contact region 2 comprises SEQ ID NO: 105, or an amino acid sequence that differs from SEQ ID NO: 105 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): I52V, L55F, G61A, P62S, G66A, and G66R, in any combination. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 150. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0008] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising an amino acid sequence selected from SEQ ID NOs: 91, 95, 96, and 99;(ii) a heavy chain contact region 2 comprising an amino acid sequence selected from SEQ ID NOs: 105, 141, and 142; and(iii) a heavy chain contact region 3 comprising ATETALVVTGTYFLHYFDN (SEQ ID NO: 135); and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 150. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0009] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises a heavy chain variable domain comprising a CDR3 comprising or consisting of ATETALVVTGTYFLHYFDN (SEQ ID NO: 135). In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises a heavy chain variable domain comprising a CDR3 comprising the following amino acid substitutions relative to SEQ ID NO: 10: S105T, E106G, L109F and P110L. In some embodiments, the heavy chain variable domain comprises a heavy chain contact region 1 comprising SEQ ID NO: 91, or an amino acid sequence that differs from SEQ ID NO: 91 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): E30Q, E30G, D31G, 133 V, I34V, and N35S, in any combination. In some embodiments, the heavy chain variable domain comprises a heavy chain contact region 2 comprising SEQ ID NO: 105, or an amino acid sequence that differs from SEQ ID NO: 105 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): 15 IM, 152V, L55F, T57A, H59Y, G61A, P62S, G66A, and G66R, in any combination. In some embodiments, the antibody or antigen binding fragment comprises a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chainCDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 150. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0010] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 150, 148, 326, 327, 332, 151, 332, 333, and 334, or contact regions thereof; and optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6 , and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13. In some embodiments, the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 150, 148, 332, 151, 333, and 334, or contact regions thereof.

[0011] In some embodiments, the CDR3 comprises ATETALVVTGTYFLHYFDN (SEQ ID NO: 135), the heavy chain contact region 1 comprises SEQ ID NO: 95, and the heavy chain contact region 2 comprises SEQ ID NO: 141. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 150, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0012] In some embodiments, the CDR3 comprises ATETALVVTGTYFLHYFDN (SEQ ID NO: 135), the heavy chain contact region 1 comprises SEQ ID NO: 91, and the heavy chain contact region 2 comprises SEQ ID NO: 105. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 148, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0013] In some embodiments, the CDR3 comprises ATETALVVTGTYFLHYFDN (SEQ ID NO: 135), the heavy chain contact region 1 comprises SEQ ID NO: 96, and the heavy chain contact region 2 comprises SEQ ID NO: 142. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 151, andoptionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0014] In some embodiments, the CDR3 comprises ATETALVVTGTYFLHYFDN (SEQ ID NO: 135), the heavy chain contact region 1 comprises SEQ ID NO: 95, and the heavy chain contact region 2 comprises SEQ ID NO: 105. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 333, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0015] In some embodiments, the CDR3 comprises ATETALVVTGTYFLHYFDN (SEQ ID NO: 135), the heavy chain contact region 1 comprises SEQ ID NO: 99, and the heavy chain contact region 2 comprises SEQ ID NO: 105. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 334, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0016] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having a substitution at position Pl 10 and a substitution at position Nil 5 (relative to SEQ ID NO: 10 numbering), wherein the substitution at position Pl 10 is selected from: P110S, P110A, P110L and P110I, and the substitution at position N115 is selected from: N115D, N115R, N115K, N115S, N115L, N115E, N115V, N115Q and Nil 51, and optionally further having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): A101 V, V103A, V103I, V104I, E106Q, and L109I, in any combination; and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the substitution at position Pl 10 is P110S, PllOA or P110L. In some embodiments, the substitution at position N115 is selected from: N115D, N115R, N115K, N115S, N115L, N115V, N115E, and Nil 5Q. In some embodiments, the substitution at position N115 is selected from: Nil 5D, Nil 5R, N115K andN115S. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 146. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0017] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 133, 134, 152, 169, 172, 176, 181, 182, 186, 203, 204, 205, 212, and 215; and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 146. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0018] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 146, 147, 243, 246-250, 256, 260, 263, 267, 268, 272, 273, 277, 287, 294-296, 303, 306, 312, 313, 317, 329, and 330, or contact regions thereof; and optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13. In some embodiments, the heavy chain variable domain comprises an amino acidsequence selected from SEQ ID NOs: 146, 147, 243, 260, 263, 267, 272, 273, 277, 294-296, 303, 306, and 330, or contact regions thereof.

[0019] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 133. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 146, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0020] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 172. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 263, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0021] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 181. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 272, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0022] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 182. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 273, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0023] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 186. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 277, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0024] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 203. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 294, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0025] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 212. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 303, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0026] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 134. In some embodiments, the heavy chain variable domain comprises the amino acidsequence of SEQ ID NO: 147, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0027] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising or an amino acid sequence that differs from SEQ ID NO: 3 by having substitutions at the following positions (relative to SEQ ID NO: 10 numbering):(a) a substitution at position Al 01 selected from A101G, A101T, A101I, and A101V;(b) at least two, three or more substitutions selected from: T100I, T100D, TIOOS, T100Y, L102V, L102I, V103L, V103I, V103A, E106D, T107Q, L109F, L109I, L109A, P110A, P110G, F113L, F113Y, N115Q, N115K, and Nil 5R, in any combination; and(c) optionally, a substitution VI 041 and / or E99Q; and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the substitution at position A101 is A101G or A101I, and wherein the two, three or more substitutions in the heavy chain contact region 3 are selected from: TIOOS, L102V, V103L, V104I, L109I, P110A, F113Y, F113L, N115K, and N115Q. In some embodiments, the substitution in T100 is selected from: T100I, T100D and TIOOS. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0028] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 132, 152, 153,188, 194, 198, 203, 212, 218, 220, and 227; and(2) optionally, comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO:243. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0029] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 145, 243,244, 279, 283, 284, 285, 289, 290, 294, 302, 303, 304, 305, 307, 308, 309-316, and 318, or contact regions thereof; and optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13. In some embodiments, the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 145, 243, 244, 279, 285, 289, 294, 303, 309, 311, and 318, or contact regions thereof.

[0030] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 152. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 243, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0031] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 194. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 285, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0032] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 198. In some embodiments, the heavy chain variable domain comprises the amino acidsequence of SEQ ID NO: 289, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0033] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 218. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 309, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0034] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 227. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 318, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0035] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 132. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 145, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0036] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having amino acid substitutions at two or three of the positions selected from LI 02, Nil 5 and VI 04 (relative to SEQ ID NO: 10 numbering), wherein the substitution at L102 is L102I or L102V, the substitution at N115 is N115R, N115H, N115K or N115Q, the substitution at VI 04 is V104A, VI 041, or V104L; and optionally, further comprising one or more amino acid substitutions selected from: E99D, T100D, A101G, V103L, V103I, L109A, L109V, L109I, P110A, P110I, F113W and F113L; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the substitution at position V104 is V 1041 or VI 04A, and the substitution at position N115 is N115Q, N115K or N115R, and optionally, further comprising one or more amino acid substitutions selected from: A101G, LI 091, L109A, P110A, and F113L. In some embodiments, the substitution at position VI 04 is V104A. In some embodiments, the heavy chain variable domain has at least 75%, 80%,85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0037] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 152, 164, 169, 171, 172, 174, 181, 182, 195, 227, 228, 231, and 232; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0038] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 243, 245, 254, 255, 257, 258, 260, 261, 262, 263, 264, 265, 266, 271, 272, 273, 276, 278, 286, 287, 292, 302, 305, 310, 318, 319, 322, and 323, or contact regions thereof; and optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13. In some embodiments, the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 243, 255, 260, 262, 263, 265, 272, 273, 286, 318, 319, 322, and 323, or contact regions thereof.

[0039] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 164. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 255, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0040] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 174. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 265, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0041] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 228. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 319, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0042] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having a substitution at position E106 and a substitution at position Y112 (relative to SEQ ID NO: 10 numbering), wherein the substitution at position E106 is selected from: E106R, E106S and E106I, and the substitution at position Y112 is selected from: Y112S, Y112G, Y112A, and Y112D, and optionally further having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): Y108I, Y108S, S105T, and H111S, in any combination; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the substitution at position E106 is E106R, E106I or E106S, and the substitution at position Y112 is Y112S, Y112G or Y112D, and optionally, further comprising one or more amino acid substitutions selected from: S105T, Y108I, and Y108S. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 297. In some embodiments, the antibody or antigen-binding fragment comprises a light chainvariable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0043] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 200, 206, 237, and 241; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 291, 297, 328, and 336, or contact regions thereof. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 297. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0044] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 200. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 291, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0045] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 206. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 297, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0046] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 241. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 336, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0047] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising or an amino acid sequence that differs from SEQ ID NO: 3 by having amino acid substitutions at the following positions (relative to SEQ ID NO: 10 numbering):(a) a substitution E99D;(b) at least two, three or more substitutions selected from: T100Y, L102V,LI 021, V103L, VI 031, V104A, V104L, LI 09V, LI 091, N115K, N115R, in any combination; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the at least two, three or more substitutions are selected from: T100Y, L102V, V103L, L104A, and L104L. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 320. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0048] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105;(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 228, 229, 230, 231, and 232; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 319, 320, 321, 322, and 323, or contact regions thereof. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity(optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 320. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0049] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 228. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 319, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0050] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 229. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 320, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0051] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 230. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 321, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0052] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 231. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 322, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0053] In some embodiments, the heavy chain contact region 3 comprises SEQ ID NO: 232. In some embodiments, the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 323, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

[0054] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having a substitution at position S105, a substitution at position Y108 and a substitution at position Hill (relative to SEQ ID NO: 10 numbering), wherein thesubstitution at position S105 is S105T or S105I, the substitution at position Y108 is selected from: Y108I, Y108S or Y108E, and the substitution at position Hill is Hl 11 S or Hl HR; and (2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6. In some embodiments, the substitution at S105 is S 1051, the substitution at Y108 is Y108E, and the substitution at Hl 11 is Hl 11R. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 282. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0055] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 191; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 282. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 282. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0056] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 102;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 139;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 3; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 144. In some embodiments, the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0057] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 102;(ii) a heavy chain contact region 2 comprising an amino acid sequence that differs from SEQ ID NO: 105 in having an amino acid substitution at position G50 (relative to SEQ ID NO: 10 numbering), wherein the substitution is G50C or G50S;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 3; and(2) optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6. In some embodiments, the antibody or antigen-binding fragment have the following substitutions relative to SEQ ID NO: 10: L28F, D31H, Y32C, N35S, G50S, and H59R. In some embodiments, the heavy chain variable domain has at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10. In some embodiments, the antibody or antigen-binding fragment comprises a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0058] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising contact regions 1, 2, and 3 of an antibody selected from: SEQ ID NOs: 25, 28, 143, 144, 145, 146, 147, 148, 150, 151, 243-337; and optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0059] In some aspects, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 25, 28, 143, 144, 145, 146, 147, 148, 150, 151, 243-337; and optionally comprising a light chain variable domain comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and further optionally the light chain variable domain has at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13.

[0060] In some embodiments, the heavy chain variable region amino acid substitutions (relative to SEQ ID NO: 10) provided herein are the only substitutions in the CDRs and / or heavy chain contact regions 1, 2 and / or 3 relative to SEQ ID NO: 10. In some embodiments, the heavy chain variable region amino acid substitutions (relative to SEQ ID NO: 10) provided herein are the only substitutions in the heavy chain contact regions 1, 2 and 3 relative to SEQ ID NO: 10. In some embodiments, the heavy chain variable region amino acid substitutions (relative to SEQ ID NO: 10) provided herein are the only substitutions relative to SEQ ID NO: 10.

[0061] In some embodiments, the light chain variable domain of any of the antibodies or antigen binding fragments described herein comprises an amino acid sequence having at least 90%, 95%, 97%, 98% or 99% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the light chain variable domain of any of the antibodies or antigen binding fragments described herein comprises the amino acid sequence of SEQ ID NO: 13.

[0062] In some embodiments, an antibody or antigen-binding fragment disclosed herein is a monoclonal antibody. In some embodiments, an antibody or antigen-bindingfragment disclosed herein is a human, humanized, or chimeric antibody. In some embodiments, an antibody or antigen-binding fragment disclosed herein is a human monoclonal antibody.

[0063] In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises an IgGl heavy chain constant region. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a human IgG 1 heavy chain constant region comprising an Fc region comprising substitutions M252Y, S254T, and T256E, or Y at position 252, T at position 254, and E at position 256, wherein the position numbering corresponds to EU numbering. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a heavy chain constant region comprising at least 50%, 75%, 80%, 85%, 90% or 95% amino acid sequence identity to SEQ ID NO: 1824. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a heavy chain constant region of SEQ ID NO: 1824. In some embodiments, an antibody or antigenbinding fragment disclosed herein comprises a heavy chain constant region comprising at least 50%, 75%, 80%, 85%, 90% or 95% amino acid sequence identity to SEQ ID NO: 1825. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a heavy chain constant region of SEQ ID NO: 1825.

[0064] In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises kappa light chain constant region. In some embodiments, an antibody or antigen-binding fragment disclosed herein is a human recombinant IgGl kappa monoclonal antibody. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a light chain constant region comprising at least 50%, 75%, 80%, 85%, 90% or 95% amino acid sequence identity to SEQ ID NO: 1826. In some embodiments, an antibody or antigen-binding fragment disclosed herein comprises a heavy chain constant region of SEQ ID NO: 1826.

[0065] In some embodiments, an antibody or antigen-binding fragment disclosed herein is an antigen-binding fragment, optionally which is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab')2 fragment.

[0066] In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV subtype A strain and / or RSV subtype B strain. In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 equal to or less than 50 ng / mL, 40 ng / mL, 30 ng / mL, 25 ng / mL, 20 ng / mL, 15 ng / mL, 10 ng / mL, 5ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL. In some embodiments, the IC50 is an average IC50 (such as an average IC50 measured in repeated experiments using the same assay, e.g., repeated at least 3, 4, 5, 6, 7, 8, or 10 times).

[0067] In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 lower than the IC50 achieved by 1G7 antibody in the same assay (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 1.1X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X, 1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X lower than the IC50 achieved by 1G7 antibody in the same assay (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823). In some embodiments, the assay is any cell based RSV virus neutralization assay known in the art or described herein. The “X” refers to fold improvement (in RSV neutralization activity or IC50 relative to the 1G7 antibody).

[0068] In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an average IC50 lower than the average IC50 achieved by 1G7 antibody (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an average IC50 at least 1.1X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X, 1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X lower (e.g., at least 1.5X lower, at least 2X lower or at least 4X lower) than the average IC50 achieved by 1G7 antibody (wherein the 1G7 antibody is anantibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823).

[0069] In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 1.2X lower than the IC50 achieved by the 1G7 antibody (e.g., in the same assay). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 1.5X lower than the IC50 achieved by the 1G7 antibody (e.g., in the same assay). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 2X lower than the IC50 achieved by the 1G7 antibody (e.g., in the same assay). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 3X lower than the IC50 achieved by the 1G7 antibody (e.g., in the same assay). In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 4X, 5X or 8X lower than the IC50 achieved by the 1G7 antibody (e.g., in the same assay).

[0070] In some embodiments, the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 lower than the IC50 achieved by 1G7 antibody selected from the antibodies listed in Table 9 and antigen-binding fragments thereof (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823). See Example 7, where the antibodies listed in Table 9 are shown to achieve lower IC50 than the 1G7 antibody. In some embodiments, the antibody or antigen-binding fragment thereof is selected from the antibodies listed in Table 9 (or antigen binding fragments thereof) and shown in Table 9 to be effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 of at least 1.1X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X,1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X lower (optionally, at least 1.5X, 2X, 3X, 4X or 8X lower) than the IC50 achieved by the 1G7 antibody. In some embodiments, the antibody or antigen-binding fragment thereof is selected from the antibodies listed in Table 9 (or antigen binding fragments thereof) and shown in Table 9 to be effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 of at least 2X lower than the IC50 achieved by the 1G7 antibody.

[0071] In some aspects, provided herein is an agent comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is equal to or less than 10 ng / mL, 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL; and(ii) means for increasing half-life of the agent.

[0072] In some embodiments, the IC50 is an average IC50, and / or wherein the IC50 is equal to or less than 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL.

[0073] In some aspects, provided herein is an agent comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is better than the IC50 achieved by 1G7 antibody (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823); and (ii) means for increasing half-life of the agent. In some embodiments, the IC50 is an average IC50. In some embodiments, the IC50 is an IC50 measured in the same assay (i.e., measured in the same assay for the test agent and the 1G7 antibody).

[0074] In some aspects, provided herein is an agent comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is at least 1.1X, 1.2X, 1.5X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X better than the IC50 achieved by 1G7 antibody (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823); and(ii) means for increasing half-life of the agent. In some embodiments, the IC50 is an average IC50 (such as an average IC50 measured in repeated experiments using the same assay,e.g., repeated at least 3, 4, 5, 6, 7, 8, or 10 times). In some embodiments, the IC50 is an IC50 measured in the same assay (i.e., measured in the same assay for the test agent and the 1G7 antibody). In some embodiments, the IC50 is at least 1. IX better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 1.2X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 1.5X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 1.7X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 2X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 3X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 4X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 5X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 6X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 7X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 8X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 10X better than the IC50 achieved by the 1G7 antibody.

[0075] In some aspects, provided herein is an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof disclosed herein or an agent disclosed herein.

[0076] In some aspects, provided herein is a vector comprising an isolated nucleic acid disclosed herein.

[0077] In some aspects, provided herein is a host cell comprising an isolated nucleic acid disclosed herein or a vector disclosed herein.

[0078] In some aspects, provided herein is a pharmaceutical composition, comprising:(i) an antibody or antigen-binding fragment thereof disclosed herein or an agent disclosed herein; and(ii) a pharmaceutically acceptable carrier or excipient.

[0079] In some aspects, provided herein is a pharmaceutical composition, comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is equal to or less than 10 ng / mL, 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL,(b) a pharmaceutically acceptable carrier or excipient.

[0080] In some embodiments, the IC50 is an average IC50, and / or wherein the IC50 is equal to or less than 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL.

[0081] In some aspects, provided herein is a pharmaceutical composition, comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is better than the IC50 achieved by 1 G7 antibody; and(b) a pharmaceutically acceptable carrier or excipient.

[0082] In some aspects, provided herein is a pharmaceutical composition, comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is at least 1.1X, 1.2X, 1.5X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X better than the IC50 achieved by 1G7 antibody (wherein the 1G7 antibody is an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823); and(b) a pharmaceutically acceptable carrier or excipient. In some embodiments, the IC50 is an average IC50 (such as an average IC50 measured in repeated experiments using the same assay, e.g., repeated at least 3, 4, 5, 6, 7, 8, or 10 times). In some embodiments, the IC50 is an IC50 measured in the same assay (i.e., measured in the same assay for the test agent and the 1G7 antibody). In some embodiments, the IC50 is at least 1.1X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 1.2X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 1.5X better than the IC50 achieved by the 1 G7 antibody. In some embodiments, the IC50 is at least 1 ,7X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 2X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 3X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 4X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 5X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 6X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 7X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 8X better than the IC50 achieved by the 1G7 antibody. In some embodiments, the IC50 is at least 10X better than the IC50 achieved by the 1G7 antibody.

[0083] In some embodiments, the pharmaceutical composition is formulated for parenteral administration. In some embodiments, the pharmaceutical composition is formulated for intramuscular injection. In some embodiments, the pharmaceutical composition is formulated for subcutaneous injection.

[0084] In some aspects, provided herein is a method of preventing Respiratory Syncytial Virus (RSV) infection in a subject, wherein the method comprises administering to the subject an antibody or antigen-binding fragment thereof disclosed herein, an agent disclosed herein, or a pharmaceutical composition disclosed herein.

[0085] In some aspects, provided herein is a method of preventing Respiratory Syncytial Virus (RSV) disease in a subject, wherein the method comprises administering to the subject an antibody or antigen-binding fragment thereof disclosed herein, an agent disclosed herein, or a pharmaceutical composition disclosed herein.

[0086] In some aspects, provided herein is a method of treating Respiratory Syncytial Virus (RSV) disease in a subject, wherein the method comprises administering to the subject an antibody or antigen-binding fragment thereof disclosed herein, an agent disclosed herein, or a pharmaceutical composition disclosed herein.

[0087] In some embodiments, the RSV disease is RSV lower respiratory tract disease. In some embodiments, the subject is a human subject. In some embodiments, the human subject is at an increased risk of RSV infection or RSV disease. In some embodiments, the human subject is an infant born prematurely, a child under 24 months of age, an adult over 65 years of age, a subject with a chronic lung disease, a subject with a chronic heart disease, or an immunocompromised subject. In some embodiments, the human subject is an infant in a first year of life or less than 1 year old. In some embodiments, the human subject is an infant treated during first RSV season of life. In some embodiments, the human subject is an infant under 24 months of age. In some embodiments, the human subject is an infant treated during first or second RSV season of life.

[0088] In some embodiments, the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered parenterally. In some embodiments, the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered intramuscularly. In some embodiments, the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of less than 10 mg / kg, or equal to or less than 7.5 mg / kg. In some embodiments, the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of equal to or less than 5 mg / kg, 4 mg / kg, 3 mg / kg, 2.5 mg / kg, 2 mg / kg, or 1 mg / kg. In some embodiments, the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of equal to or less than 5 mg, 10 mg, 20 mg, 25 mg, 50 mg, 75 mg, or 100 mg (optionally, 5 mg to 25 mg for children less than 5 kg, and 10 mg to 50 mg for children 5 kg or more). Insome embodiments, the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered subcutaneously.

[0089] In some aspects, provided herein is a method of manufacturing an anti- Respiratory Syncytial Virus (RSV) antibody or antigen-binding fragment thereof disclosed herein, wherein the method comprises culturing a host cell disclosed herein under conditions suitable for expressing the antibody or antigen-binding fragment thereof, followed by recovering the antibody or antigen-binding fragment thereof from the host cell, and optionally followed by purifying the antibody or antigen-binding fragment thereof.

[0090] In some aspects, provided herein is a kit comprising: a) an antibody or antigen-binding fragment thereof disclosed herein, an agent disclosed herein, or a pharmaceutical composition disclosed herein; and b) instructions for administration of the antibody or antigen-binding fragment thereof to prevent or treat Respiratory Syncytial Virus (RSV) infection or RSV disease.BRIEF DESCRIPTION OF THE DRAWINGS

[0091] FIGS. 1A-1D show ELISA binding activity of RSV antibodies to recombinant DS-CaVl antigen. FIG. 1 A shows binding results for antibodies 1101, 1103, 1105, 1106, 1107, 1109, and 1110. FIG. IB shows binding results for antibodies 1111, 1112, 1113, 1115, 1116, and 1117 variants. FIG. 1C shows binding results for antibodies 1202, 1203, 1204, 1206, and 1207. FIG. ID shows binding results for antibodies 1201, 1208, 1209, 1210, 1211, and 1212. The binding results in FIGS. 1A-1D are shown relative to 1G7 (positive control) and isotype control mAb (negative control).

[0092] FIG. 2 shows RSV neutralization activity (IC50) of antibodies 1109, 1111, 1115, 1204, and 1211. RSV neutralization activity by the antibodies was tested in comparison to the 1G7 antibody (positive control) using a microneutralization assay with a commercially available recombinant RSV A2 that expresses firefly luciferase. Symbols: 1109 (closed circle), 1111 (square), 1115 (triangle), 1204 (inverted triangle), 1211 (diamond) and 1G7 (open circle).

[0093] FIG. 3 shows lung RSV titers in a cotton rat RSV challenge model following administration of antibodies 131311, 1304, and 1 (where antibody labeled in the figure as “1325” is identical to antibody 1 described herein). RSV neutralization activity by the antibodies was tested in comparison to the 1G7 antibody (positive control) and an isotype control (negative control). Antibodies were administered at 2.0 mg / kg or 0.25 mg / kg. The figure shows measured viral titers in lungs 5 days post-infection with RSV / A2 virus and 6 dayspost administration of either a negative control, 1G7 (nirsevimab), or tested antibody at the shown doses. The data shows a geometric mean of logic values with standard deviations, starting from the lowest value of 200 plaque-forming units per gram of tissue, or Logio=2.301 pfu / g, which was the lowest level of detection (LOD) for this study.

[0094] FIG. 4 shows RS V neutralization activity (EC50 and EC90) of antibody 131311 in comparison to antibody 1G7 in a cotton rat RSV challenge model. EC50 and EC90 are calculated antibody doses needed to achieve 50% and 90% protection from viral infection.DETAILED DESCRIPTION

[0095] In some aspects, provided herein are improved antibodies and antigen-binding fragments thereof that specifically bind to Respiratory Syncytial Virus (RSV). In some embodiments, provided herein are antibodies or antigen binding fragments thereof having the CDRs (e.g., heavy chain CDRs, or both heavy chain and light chain CDRs) of the improved antibodies described herein. In some embodiments, provided herein are antibodies or antigen binding fragments thereof having the heavy chain contact regions (e.g., HC contact region 1 and / or HC contact region 2) of the improved antibodies described herein. In some embodiments, provided herein are antibodies or antigen binding fragments thereof having the variable regions (e.g., heavy chain variable region, or both heavy chain variable region and light chain variable region) of the improved antibodies described herein.

[0096] In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of less than 75 ng / mL, less than 70 ng / mL, less than 60 ng / mL, less than 50 ng / mL, less than 45 ng / mL, less than 40 ng / mL, less than 35 ng / mL, less than 30 ng / mL, or less than 25 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of less than 20 ng / mL, less than 15 ng / mL, less than 10 ng / mL, less than 5 ng / mL, less than 3 ng / mL, less than 2 ng / mL, or less than 1 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of less than 10 ng / mL, less than 5 ng / mL, less than 3 ng / mL, less than 2 ng / mL, or less than 1 ng / mL. In some embodiments, antibodiesand antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of less than 5 ng / mL, less than 3 ng / mL, less than 2 ng / mL, or less than 1 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of equal to or less than 4 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of equal to or less than 3 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of equal to or less than 2.5 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of equal to or less than 2 ng / mL. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), with an IC50 of equal to or less than 1 ng / mL.

[0097] In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least 1.1X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X, 1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 5.5X, 6X, 6.5X, 7X, 7.5X, 8X, 8.5X, 9X, 9.5X, 10X, 10.5X, 11X, 12X, 13X, 14X, 15X, 16X, 17X, 18X, 19X, or 20X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, or 5X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen -binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that describedherein or known in the art), that is at least or more than 1.5X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 2X higher relative to 1G7 antibody. In some embodiments, antibodies and antigenbinding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 2.5X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 3X higher relative to 1G7 antibody. In some embodiments, antibodies and antigenbinding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 4X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 5X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen -binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 7.5X higher relative to 1G7 antibody. In some embodiments, antibodies and antigen-binding fragments thereof provided herein achieve RSV neutralization activity (e.g., against recombinant RSV A2 and / or in a cell-based virus neutralization assay such as that described herein or known in the art), that is at least or more than 10X higher relative to 1G7 antibody. The “X” refers to fold improvement (in RSV neutralization activity or IC50 relative to the 1G7 antibody).

[0098] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is an immunoglobulin. In some embodiments, an antigen-binding fragment of any antibody described herein is used in the compositions and methods described herein.

[0099] In some aspects, provided herein are methods of prevention and treatment of RSV infection or disease using the improved antibodies, antigen-binding fragments thereof, described herein.

[0100] The antibodies described herein exert significantly increased neutralizing activity against RSV, relative to known anti -RSV antibodies, such as 1G7 antibody (having VH of SEQ ID NO: 10 and VL of SEQ ID NO: 13). The antibodies of the present invention and antigen-binding fragments thereof, with their improved neutralizing activity, may be used to produce anti-RSV therapeutics with improved economy, potency, safety, and other beneficial features. Examples provided herein show successful binding of the antibodies described herein to the RSV glycoprotein, and demonstrate their potent RSV neutralizing activity superior to that of the previously known antibody (1G7).

[0101] In some embodiments, the antibodies described herein with improved neutralization potency against RSV, and antigen-binding fragments thereof, are suitable for treatment of a variety of subjects or patients. In some embodiments, the patient is at risk of RSV. In some embodiments, the patient has (e.g., has been diagnosed with) RSV infection. In some embodiments, the patient is a human. In some embodiments, the patient is an infant. In some embodiments, the patient is up to 24 months of age. In some embodiments, the patient is up to 12 months of age. In some embodiments, the patient is up to 6 months of age. In some embodiments, the patient is older than 24 months of age. In some embodiments, the patient is an adult. In some embodiments, the patient is 65 years or older. In some embodiments, the patient has a severe respiratory disease. In some embodiments, the patient is immunocompromised.

[0102] In some embodiments, the antibodies described herein with improved neutralization potency against RSV, and antigen-binding fragments thereof, are suitable for administration at a lower dose than known antibodies (such as 1G7). In some embodiments, the lower dose is less than 10 mg / kg. In some embodiments, the lower dose is 7.5 mg / kg or less. In some embodiments, the lower dose is 5 mg / kg or less. In some embodiments, the lower dose is 2.5 mg / kg or less. In some embodiments, the lower dose is 2 mg / kg or less. In some embodiments, the lower dose is about 1 mg / kg. In some embodiments, the dose is from 1 mg / kg to 10 mg / kg. In some embodiments, the dose is from 1 mg / kg to 7.5 mg / kg. In some embodiments, the dose is from 1 mg / kg to 5 mg / kg. In some embodiments, the dose is from 1 mg / kg to 7.5 mg / kg. In some embodiments, the dose is from 1 mg / kg to 2.5 mg / kg. In some embodiments, the dose is from 1 mg / kg to 7.5 mg / kg. In some embodiments, the dose is from1 mg / kg to 2 mg / kg. In some embodiments, the dose is from 1 mg / kg to 7.5 mg / kg. In some embodiments, the dose is from 1 mg / kg to 1.5 mg / kg.

[0103] As described herein, the term “1G7” or “1G7 antibody” refers to an antibody having VH of SEQ ID NO: 10, VL of SEQ ID NO: 13, the kappa light constant region and the C7 / l -hinge-C7 / 2-C7 / 3 IgGl heavy constant region. The “1G7” antibody also has the HC of SEQ ID NO: 1822 and the LC of SEQ ID NO: 1823. The 1G7 antibody is known in the art as “nirsevimab.” In the experiments presented in the example section, the 1G7 antibody was expressed using 1G7 VH expression plasmid sequence of SEQ ID NO: 12 and 1G7 VL expression plasmid sequence of SEQ ID NO: 15.Terminology

[0104] Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, chemistry, biochemistry, molecular biology, pharmacology and toxicology are those well-known and commonly used in the art.

[0105] The articles “a” and “an,” as used herein, refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0106] A “subject” is a human or a non-human animal. This term includes mammals, such as humans, primates, livestock animals, companion animals and animal models of disease.

[0107] “Administering” or “administration of’ to a subject can be carried out using one of a variety of methods known to those skilled in the art. In some embodiments, the administration is parenteral. For example, an antibody or fragment can be administered, intravenously or intramuscularly. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0108] The term an “effective amount” or a “therapeutically effective amount” of an antibody or fragment, as used herein, is an amount of antibody that, when administered to a subject will have or expected to have a therapeutic effect. The therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or moreadministrations. The precise effective amount needed for a subject will depend upon, for example, the subject’s size, health and age, and the nature and extent of the condition being treated.

[0109] The term “monoclonal antibody,” as used herein, refers to an antibody member of a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier “monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. A monoclonal antibody can be produced by any techniques including non-hybridoma techniques, e.g., by recombinant techniques.

[0110] The term “treating” an infection or disease in a subject, as used herein, refers to administering an antibody or fragment to the subject having or suspected of having an infection or disease (i.e., after the onset of the infection or disease), such that at least one symptom of the infection or disease is decreased or prevented from worsening. Desirable effects of treatment include decreasing the rate of progression, ameliorating or palliating the pathological state, and remission or improved prognosis of the infection or disease. An individual is successfully “treated,” for example, if one or more symptoms associated with an infection or disease are mitigated or eliminated.

[0111] The term “preventing” an infection or disease in a subject, as used herein, refers to administering an antibody or fragment to the subject prior to the onset of the infection or disease, when administration of the antibody or fragment to a statistical sample prior to the onset of the infection or disease reduces the occurrence of the infection or disease in the treated sample relative to an untreated control sample, or delays the onset or reduces the occurrence or severity of one or more symptoms of the infection or disease relative to the untreated control sample.

[0112] The term “about,” when used to modify a numeric value herein, indicate that deviations of up to 10% above and below the numeric value remain within the intended meaning of the recited value. In some embodiments, the deviation is up to about 7.5%, 6%, 5%, 4%, 3%, 2% or 1% above and below the recited value.

[0113] The term “VL,” as used herein, refers to the light chain variable domain or region of an antibody.

[0114] The term “VH,” as used herein, refers to the heavy chain variable domain or region of an antibody.

[0115] The term “LC,” as used herein, refers to the light chain of an antibody.

[0116] The term “HC,” as used herein, refers to the heavy chain of an antibody.

[0117] The terms “heavy chain contact region(s)” or “HC contact region(s),” as used herein, refer to the regions determined by the inventors to interact with the RSV F A2 antigen based on the crystal structure of 1G7 bound to RSV F A2 (rcsb.org / structure / 5udc, 5UDC: Crystal Structure of RSV F A2 Bound to MEDI8897) and structural modeling. Such HC contact region(s) contain the complementarity determining regions (CDRs) as determined using IMGT as described herein, and may contain short adjacent framework regions as described herein (see, e.g., Table 2). As determined by the inventors, HC contact region 1 contains the HC CDR1 and small parts of framework regions adjacent thereto as shown in, e.g., Table 2. As determined by the inventors, HC contact region 2 contains the HC CDR2 and small parts of framework regions adjacent thereto as shown in, e.g., Table 2. As determined by the inventors, HC contact region 3 contains the same amino acid sequence as HC CDR3.

[0118] The term “percent (%) amino acid sequence identity” or “percent sequence identity,” as used herein, with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known in the art, for instance, using publicly available computer software such as BLASTp, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software.Improved Antibodies or Antigen Binding Fragments Thereof described herein

[0119] In some aspects, provided herein are RSV-specific antibodies and antigen binding fragments thereof having improved properties as compared to known antibodies, e.g., 1G7 antibody (having VH of SEQ ID NO: 10 and VL of SEQ ID NO: 13).

[0120] In some embodiments, the antibody or antigen-binding fragment thereof described herein specifically binds RSV subtype A strain and / or RSV subtype B strain (e.g.,protein F). In some embodiments, the antibody or antigen-binding fragment thereof described herein is effective at neutralizing RSV subtype A strain (e.g., RSV A2 strain) and / or RSV subtype B strain. In some embodiments, the antibody or antigen-binding fragment thereof described herein specifically binds RSV F A2 (RSV strain A2, Fusion glycoprotein F).

[0121] In some embodiments, the antibodies and antigen-binding fragments thereof described herein exhibit improved neutralization of RSV (e.g., lower EC50 or IC50 values) relative to 1G7 antibody. In some embodiments, the lower EC50 or IC50 virus neutralization values are at least 1.1 X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X, 1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 5.5X, 6X, 6.5X, 7X, 7.5X, 8X, 8.5X, 9X, 9.5X, 10X, 10.5X, 11X, 12X, 13X, 14X, 15X, 16X, 17X, 18X, 19X, or 20X lower relative to 1G7 antibody. In some embodiments, the lower EC50 or IC50 virus neutralization values are at least 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, or 5X lower relative to 1G7 antibody. In some embodiments, the antibodies and antigenbinding fragments thereof described herein exhibit an improved affinity for RSV (e.g., lower ELISA EC50 concentration) relative to 1G7 antibody. In some embodiments, the lower ELISA EC50 values are at least 1.1X, 1.2X, 1.3X, 1.4X, 1.5X, 1.6X, 1.7X, 1.8X, 1.9X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 5.5X, 6X, 6.5X, 7X, 7.5X, 8X, 8.5X, 9X, 9.5X, 10X, 10.5X, 11X, 12X, 13X, 14X, 15X, 16X, 17X, 18X, 19X, or 20X lower relative to 1G7 antibody. In some embodiments, the lower ELISAEC50 values are at least 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, or 5X lower relative to 1G7 antibody. In some embodiments, the RSV neutralization is assessed in a cell-based virus neutralization assay such as that described herein or known in the art, e.g., against recombinant RSV A2. In some embodiments, the RSV neutralization is assessed in in an animal model in vivo as described herein or known in the art. In some embodiments, the antibodies and antigen-binding fragments thereof are particularly suitable for neutralizing and / or preventing an RSV infection and / or adverse effects of an RSV infection.Complementarity Determining Regions and Variable Regions

[0122] Complementarity Determining Regions (CDRs) are defined in various ways known in the art including using the Kabat, Chothia, AbM, Contact, and IMGT systems.

[0123] In some embodiments, the CDRs of an antibody can be defined according to the IMGT system (see “IMGT®, the international ImMunoGeneTics information system® website imgt.org, founder and director: Marie-Paule Lefranc, Montpellier, France; see, e.g., Lefranc, M.-P, 1999, The Immunologist, 7: 132-136 and Lefranc, M.-P. et al., 1999, Nucleic Acids Res., 27:209-212, both of which are incorporated herein by reference in their entirety). In some embodiments, the CDRs of an antibody can be defined according to the IMGT V-QUEST toolfor CDR analysis (www.imgt.org / FAQ / Vquest.php). The IMGT CDR positions may vary depending on the antibody, and may be determined according to methods known in the art. In some embodiments, the CDRs of the antibodies described herein are determined using the IMGT system. In some embodiments, the CDRs described herein are defined using IMGT / V- QUEST program (Brochet, X., Lefranc, M.-P and Giudicelli, V. Nucl. Acids Res. 36, W503- 508 (2008); Giudicelli, V, Brochet, X., Lefranc, M.-P. Cold Spring Harb Protoc. 2011 Jun l;2011(6)), version 3.6.3 (30 January 2024), reference directory release: 202430-2 (23 July 2024).

[0124] In other embodiments, the CDRs of an antibody can be defined according to another system, e.g., Kabat, Chothia, AbM or Contact, according to methods known in the art. For example, the Kabat system is based on sequence variability (see, e.g., Kabat E A & Wu T T (1971) Ann NY Acad Sci 190: 382-391; Kabat E A et al, (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242.

[0125] From N-terminus to C-terminus, both the light and heavy chain variable domains comprise the regions Framework Region (“FR”) 1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of, e.g., IMGT, Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987), or Chothia et al., Nature 342:878-883 (1989), each of which are hereby incorporated by reference herein in their entirety).

[0126] In some embodiments, provided herein are anti-RSV antibodies designated “1” to “95”, “1101”, “1103”, “1105”, “1106”, “1107”, “1109”, “1110”, “1111”, “1112”, “1113”, “1115”, “1116”, “1117”, “1201”, “1202”, “1203”, “1204”, “1206”, “1207”, “1208”, “1209”, “1210”, “1211”, “1212”, “1215”, “1216”, “1303”, “1304”, “1306”, “1313”, “131307”, “131311”, and “131314”, and antigen-binding fragments thereof, the sequences of which are provided herein (see, e.g., the Tables provided herein). In some embodiments, provided herein is anti-RSV antibody designated “1109,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1111,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1115,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1204,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1211,” or an antigen-bindingfragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1101,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1103,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1105,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1106,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1107,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1110,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1112,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1113,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1116,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1117,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1201,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1202,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1203,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1206,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1207,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1208,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1209,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1210,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1212,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1215,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1216,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1303,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “1304,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1306,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated“1313,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “131307,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti -RS V antibody designated “131311,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “131314,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “1,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “2,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “3,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “4,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “5,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “6,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “7,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “8,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “9,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “10,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “11,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “12,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “13,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “14,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “15,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “16,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “17,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “18,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “19,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “20,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “21,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “22,” or an antigen-binding fragment thereof. In someembodiments, provided herein is anti-RSV antibody designated “23,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “24,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “25,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “26,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “27,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “28,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “29,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “30,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “31,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “32,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “33,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “34,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “35,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “36,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “37,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “38,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “39,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “40,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “41,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “42,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “43,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “44,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “45,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “46,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “47,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “48,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “49,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “50,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “51,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “52,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “53,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “54,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “55,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “56,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “57,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “58,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “59,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “60,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “61,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “62,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “63,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “64,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “65,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “66,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “67,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “68,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “69,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “70,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “71,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “72,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “73,” or an antigen-binding fragment thereof. In some embodiments, provided herein is antiRSV antibody designated “74,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “75,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “76,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “77,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “78,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “79,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “80,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “81,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “82,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “83,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “84,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “85,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “86,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “87,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “88,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “89,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “90,” or an antigenbinding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “91,” or an antigen -binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “92,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “93,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti-RSV antibody designated “94,” or an antigen-binding fragment thereof. In some embodiments, provided herein is anti- RSV antibody designated “95,” or an antigen-binding fragment thereof. The sequences of the heavy chain variable domains of the above-referenced anti-RSV antibodies are provided herein (see e.g., Table 3 and the Table of Sequences). Each of the above-referenced anti-RSV antibodies comprises the light chain variable domain sequence of SEQ ID NO: 13. The antigenbinding fragments of the above-referenced anti-RSV antibodies comprise the heavy chain contact regions 1, 2 and 3 (where the contact region 3 is identical to CDR3) that are shown inthe Tables provided herein (e.g., Table 2, Table 2.1, and the Table of Sequences) for each of these antibodies. Generally, references to antibodies by the same number throughout the disclosure relate to the same antibody (e.g., reference to antibody “1” or 1, with or without quotation marks, refers to the antibody having the CDRs and the contact regions set forth for antibody identified by numeral 1 in, e.g., Table 2, Table 2.1, and / or the Table of Sequences, and having the heavy chain variable region set forth for antibody identified by numeral 1 in, e.g., Table 3 and / or the Table of Sequences).

[0127] The heavy chain variable domain sequences of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314 are provided, e.g., in the Table of Sequences, and each of these antibodies comprises the light chain variable domain sequence of SEQ ID NO: 13. In some embodiments, the antigen-binding fragment of such antibodies is a region containing three or six CDRs of any of these antibodies (e.g., 3 HC CDRs of any of these antibodies, or 3 HC CDRs and 3 HL CDRs of any of these antibodies), or a region containing one or both variable domains of such antibodies (e.g., the VH of any of these antibodies, or the VH and VL of any of these antibodies). In some embodiments, the antigen-binding fragment of such antibodies is a region containing three heavy chain contact regions of any of these antibodies and, optionally, three light chain CDRs of SEQ ID NO: 13.

[0128] The heavy chain variable domain sequences of each of antibodies 1 to 95 are provided, e.g., in the Table of Sequences, and each of these antibodies comprises the light chain variable domain sequence of SEQ ID NO: 13. In some embodiments, the antigen -binding fragment of such antibodies is a region containing three or six CDRs of any of these antibodies (e.g., 3 HC CDRs of any of these antibodies, or 3 HC CDRs and 3 LC CDRs of any of these antibodies), or a region containing one or both variable domains of such antibodies (e.g., the VH of any of these antibodies, or the VH and VL of any of these antibodies). In some embodiments, the antigen-binding fragment of such antibodies is a region containing three heavy chain contact regions of any of these antibodies and, optionally, three light chain CDRs of SEQ ID NO: 13.

[0129] The CDRs of the select antibodies or antigen-binding fragments thereof described herein are shown in Table 1 (where the CDRs were determined using the IMGT system). The CDRs of other antibodies described herein are presented in, e.g., the Table of Sequences, below.TABLE 1. Select CDR sequences

[0130] In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1109 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1111 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in theart, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1115 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1204 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1211 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1215 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1216 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1303 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1304 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1306 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1313 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 131307 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 131311 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in theart, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 131314 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. The CDRs and the heavy chain contact regions are provided for the antibodies identified by these numbers in Table 2, Table 2.1 and / or the Table of Sequences.

[0131] In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 1 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 2 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 3 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 4 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 5 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 6 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 7 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 8 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 9 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 10 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 11 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 12 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 13 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 14 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 15 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 16 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 17 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 18 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 19 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 20 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 21 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 22 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 23 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 24 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 25 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 26 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 27 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 28 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 29 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 30 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 31 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 32 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 33 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 34 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 35 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 36 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 37 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 38 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 39 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 40 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 41 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 42 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 43 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 44 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 45 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 46 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 47 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 48 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 49 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 50 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 51 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 52 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 53 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 54 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 55 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 56 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 57 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 58 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 59 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 60 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 61 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 62 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 63 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 64 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 65 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 66 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 67 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 68 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 69 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 70 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 71 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 72 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 73 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 74 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 75 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 76 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 77 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 78 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 79 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 80 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 81 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 82 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 83 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 84 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 85 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 86 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally theheavy chain contact regions, of the 87 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 88 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 89 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 90 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 91 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 92 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 93 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 94 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. In some embodiments, provided herein is an anti-RSV antibody having the CDRs, and optionally the heavy chain contact regions, of the 95 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT. The CDRs and the heavy chain contact regions are provided for the antibodies identified by these numbers in Table 2, Table 2.1 and / or the Table of Sequences.

[0132] In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1101 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1101). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1105 antibody, or an antigenbinding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1105). In some embodiments, provided herein is an anti -RS V antibody having HC CDR1 of the 1106 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1106). In some embodiments, provided herein is an anti -RS V antibody having HC CDR1 of the 1107 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1107). In some embodiments, provided herein is an anti -RS V antibody having HC CDR1 of the 1109 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1109). In some embodiments, provided herein is an anti -RS V antibody having HC CDR1 of the 1110 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1110). In some embodiments, provided herein is an anti -RS V antibody having HC CDR1 of the 1111 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1111). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1112 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1112). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1113 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1113). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1115 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1115). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1116 antibody, or an antigen binding fragment thereof, where the CDRs aredefined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1116).

[0133] In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1215 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1215). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1216 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1216). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1303 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1303). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1304 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1304). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1306 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1306). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 1313 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1313). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 131307 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131307). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 131311 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131311). In some embodiments, provided herein is an anti-RSV antibody having HC CDR1 of the 131314 antibody, or an antigen binding fragment thereof, where theCDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131314).

[0134] In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1201 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1201). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1202 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1202). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1206 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1206). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1207 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1207). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1208 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1208). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1209 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1209).

[0135] In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1215 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1215). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1216 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1216). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1303 antibody, or an antigen binding fragment thereof, where the CDRs aredefined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1303). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1304 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1304). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1306 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1306). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 1313 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1313). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 131307 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131307). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 131311 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131311). In some embodiments, provided herein is an anti-RSV antibody having HC CDR2 of the 131314 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131314).

[0136] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 1303 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1303). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 1304 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1304). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 1306 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may bethe same as, or different from, the other CDRs of antibody 1306). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 1313 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1313). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 131307 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131307). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 131311 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131311). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 131314 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131314).

[0137] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 1 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 1). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 2 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 2). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 3 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 3). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 4 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 4). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 5 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 5). In some embodiments, provided herein is an anti-RSV antibodyhaving HC CDR3 of the 6 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 6). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 7 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 7). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 8 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 8).

[0138] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1, HC contact region 2, and / or HC CDR3 of the 131311 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 131311).

[0139] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 9 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 9). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 10 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 10).

[0140] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 11 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 11). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 12 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 12). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 13 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, ordifferent from, the other CDRs of antibody 13). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 14 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 14). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 15 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 15). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 16 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 16). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 17 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 17). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 18 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 18). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 19 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 19). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 20 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 20). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 21 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 21). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 22 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 22). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the23 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 23). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 24 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 24). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 25 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 25). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 26 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody26).

[0141] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 27 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody27).

[0142] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 28 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 28). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 29 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 29). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 30 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 30). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 31 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody31). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 32 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 32). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 33 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 33). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 34 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 34). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 35 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 35). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 36 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 36). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 37 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 37). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 38 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 38). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 39 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 39). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 40 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 40). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 41 antibody, or an antigen binding fragmentthereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 41). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 42 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 42). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 43 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 43). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 44 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 44). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 45 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 45). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 46 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 46). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 47 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 47). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 48 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 48). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 49 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 49). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 50 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, ordifferent from, the other CDRs of antibody 50). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 51 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 51). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 52 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 52). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 53 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 53). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 54 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 54). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 55 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 55). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 56 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 56). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 57 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 57). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 58 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 58). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 59 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 59). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the60 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 60). In some embodiments, provided herein is an anti -RS V antibody having HC CDR3 of the 61 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 61). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 62 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 62). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 63 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 63). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 64 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 64). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 65 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 65). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 66 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 66). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 67 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 67). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 68 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 68). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 69 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT(e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 69). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 70 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 70). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 71 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 71). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 72 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 72). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 73 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 73). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 74 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 74). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 75 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 75). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 76 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 76). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 77 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 77). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 78 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 78). In some embodiments, provided herein is ananti-RSV antibody having HC CDR3 of the 79 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 79). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 80 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 80). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 81 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody81).

[0143] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 82 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody82). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 83 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 83).

[0144] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1, HC contact region 2, and / or HC CDR3, of the 84 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 84). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1, HC contact region 2, and / or HC CDR3, of the 85 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 85).

[0145] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 86 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 86).

[0146] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1, HC contact region 2, and / or HC CDR3, of the 87 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 87). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1, HC contact region 2, and / or HC CDR3, of the 88 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 88).

[0147] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC contact region 2 of the 89 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 89).

[0148] In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC CDR3 of the 90 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 90). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC CDR3 of the 91 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 91). In some embodiments, provided herein is an anti-RSV antibody having HC contact region 1 and / or HC CDR3 of the 92 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 92).

[0149] In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 93 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 93). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 94 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody94). In some embodiments, provided herein is an anti-RSV antibody having HC CDR3 of the 95 antibody, or an antigen binding fragment thereof, where the CDRs are defined according to any system known in the art, e.g., IMGT (e.g., where other CDRs may be the same as, or different from, the other CDRs of antibody 95).

[0150] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which comprises HC contact region 1 of any antibody selected from: 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1215, 1216, 131307, 131311, and 131314 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 2 of any antibody selected from: 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 131307, 131311, and 131314 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 3 of any antibody selected from: 1303, 1304, 1306, 1313, 131307, 131311, and 131314 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which comprises HC contact region 1 of any antibody selected from: 1-95 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which comprises HC contact region 2 of any antibody selected from: 1-95 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which comprises HC contact region 3 of any antibody selected from: 1-95 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which comprises HC contact region 1 of any antibody selected from: 131311, 1216, 88, 1215, 90, 131314, 91, and 92 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 2 of any antibody selected from: 131311, 1216, 88, 1215, and 131314 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereofwhich comprises HC contact region 3 of any antibody selected from: 1, 1304, 131311, 2, 13, 18, 20, 21, 23, 25, 30, 31, 35, 37, 40, 43, 44, 47, 49, 1313, 52-55, 61, 64, 67, 69, 1306, 76, 1303, 77-81, 86, 88, 90, 131314, 91, 92, and 94 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 1 of any antibody selected from: 131311, 1304, and 1 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 2 of any antibody selected from: 131311, 1304, and 1 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises HC contact region 3 of any antibody selected from: 131311, 1304, and 1 (e.g., where other HC contact regions or CDRs may be the same as, or different from, said antibody’s). As described herein, the HC contact regions (HC contact region 1, HC contact region 2, and HC contact region 3) are regions determined by the inventors to interact with the RSV F A2 antigen based on the crystal structure of 1G7 bound to RSV F A2 and structural modeling, and contain the CDRs as determined using IMGT and may comprise one or more amino acids of adjacent framework regions.

[0151] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314.

[0152] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1-95. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies 1-95.

[0153] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1, 1304, 131311, 2, 13, 18, 20, 21, 23, 25, 30, 31, 35, 37, 40, 43, 44, 47, 49, 1313, 52-55, 61, 64, 67, 69, 1306, 76, 1303, 77-81, 86, 88, 90, 131314, 91, 92, 1215, 1216, and 94. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies 1, 1304, 131311, 2, 13, 18, 20, 21, 23, 25, 30, 31, 35, 37, 40, 43, 44, 47, 49, 1313, 52-55, 61, 64, 67, 69, 1306, 76, 1303, 77-81, 86, 88, 90, 131314, 91, 92, 1215, 1216, and 94.

[0154] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1, 13, 21, 23, 30, 31, 35, 40, 43, 47, 49, 52, 55, 61, 67, 76, 77, 78, 79, 80, 81, 91, 92, 94, 1216, 1303, 1304, 1306, 1313, 131311, and 131314. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies selected from: 1, 13, 21, 23, 30, 31, 35, 40, 43, 47, 49, 52, 55, 61, 67, 76, 77, 78, 79, 80, 81, 91, 92, 94, 1216, 1303, 1304, 1306, 1313, 131311, and 131314.

[0155] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1, 30, 31, 35, 43, 49, 55, 67, 76, 78, 80, 94, 1304, 1306, and 131311. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies 1, 30, 31, 35, 43, 49, 55, 67, 76, 78, 80, 94, 1304, 1306, and 131311.

[0156] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has HC contact regions of any one of antibodies 1, 1304, and 131311. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the HC contact regions relative to the HC contact regions of 1G7 as any one of antibodies 1, 1304, and 131311.

[0157] HC contact regions 1, 2, and 3 of antibodies 1G7, 1, 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314 are shown in Table 2. HC contact regions 1, 2, and 3 of antibodies 1-95 are shown in Table 2.1. As shown below, each of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111,1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, and 1216 described herein comprises HC contact region 3 which is the same as HC CDR3 of the amino acid sequence of ATETALVVSETYLPHYFDN (SEQ ID NO: 3).Attorney Docket No.: OMS-00125Attorney Docket No.: OMS-00125from parts of Framework Regions (FR) that together form the contact region. The antibody to which the respective CDRs and contact regions belong is numerically identified in the first column. The substitutions relative to the 1G7 antibody are in bold for emphasis.Attorney Docket No.: OMS-00125TABLE 2.1 Heavy Chain Contact Regions 1, 2, and 3 of Additional AntibodiesAttorney Docket No.: OMS-00125Attorney Docket No.: OMS-00125Attorney Docket No.: OMS-00125Attorney Docket No.: OMS-00125

[0158] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314. Each of antibodies 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, and 131314 described herein comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13.

[0159] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1-95. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1- 95. Each of antibodies 1-95 described herein comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13.

[0160] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1, 1304, 131311, 2, 13, 18, 20, 21, 23, 25, 30, 31, 35, 37, 40, 43, 44, 47, 49, 1313, 52-55, 61, 64, 67, 69, 1306, 76, 1303, 77-81, 86, 88, 90, 131314, 91, 92, 1215, 1216, and 94. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1, 1304, 131311, 2, 13, 18, 20, 21, 23, 25, 30, 31, 35, 37, 40, 43, 44, 47, 49, 1313, 52-55, 61, 64, 67, 69, 1306, 76, 1303, 77-81, 86, 88, 90, 131314, 91, 92, 1215, 1216, and 94.

[0161] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1, 13, 21, 23, 30, 31, 35, 40, 43, 47, 49, 52, 55, 61, 67, 76, 77, 78, 79, 80, 81, 91, 92, 94, 1216, 1303, 1304, 1306, 1313, 131311, and 131314. In some embodiments, provided herein is ananti -RS V antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 11, 13, 21, 23, 30, 31, 35, 40, 43, 47, 49, 52, 55, 61, 67, 76,77, 78, 79, 80, 81, 91, 92, 94, 1216, 1303, 1304, 1306, 1313, 131311, and 131314.

[0162] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1, 30, 31, 35, 43, 49, 55, 67, 76, 78, 80, 94, 1304, 1306, and 131311. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1, 30, 31, 35, 43, 49, 55, 67, 76,78, 80, 94, 1304, 1306, and 131311.

[0163] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1109, 1111, 1115, 1204, and 1211. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1109, 1111, 1115, 1204, and 1211.

[0164] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1303, 1304, and 1306. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1303, 1304, and 1306.

[0165] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of antibody 1215 or 1216. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one antibody 1215 or 1216.

[0166] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of antibody 1313. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one antibody 1313.

[0167] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 131307, 131311, and 131314. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 131307, 131311, and 131314.

[0168] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof which has the heavy chain variable region of any one of antibodies 1, 1304, and 131311. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof which comprises the same amino acid substitutions in the heavy chain variable region relative to the heavy chain variable region of 1G7 as any one of antibodies 1, 1304, and 131311.

[0169] The heavy chain variable region sequences of 1G7, and antibodies 1109, 1111, 1115, 1204, 1211, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, 131314, 1, 13, 21, 23, 30, 31, 35, 43, 47, 49, 52, 55, 61, 67, 76, 77, 78, 79, 80, 81, 91, 92, and 94 are shown in Table 3. Each of antibodies 1109, 1111, 1115, 1204, 1211, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, 131314, 1, 13, 21, 23, 30, 31, 35, 43, 47, 49, 52, 55, 61, 67, 76, 77, 78, 79, 80, 81, 91, 92, and 94 described herein comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13.TABLE 3. Sequences of variable regions of select antibodiesNote: Where marked, the underlined regions show the CDR sequences (IMGT), and the bolded text shows the location of substitutions.

[0170] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 7, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0171] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 8, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0172] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 9, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0173] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 117, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0174] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 118, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0175] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 119, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0176] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 120, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0177] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 121, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0178] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 122, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0179] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 123, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0180] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 124, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0181] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 125, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0182] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 126, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0183] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 127, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0184] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ IDNO: 128, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0185] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 129, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0186] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 130, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0187] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 7, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0188] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 9, CDR2 of SEQ ID NO: 131, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0189] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 132, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0190] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 133, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0191] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 134, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0192] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0193] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 8, CDR2 of SEQ ID NO: 136, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0194] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 119, CDR2 of SEQ ID NO: 130, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0195] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising heavy chain CDR1 of SEQ ID NO: 120, CDR2 of SEQ ID NO: 137, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0196] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 92, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0197] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 93, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0198] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 94, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0199] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 95, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0200] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 96, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0201] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 97, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0202] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 98, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0203] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 99, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0204] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 100, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0205] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 101, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0206] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 102, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0207] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 103, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0208] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 104, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0209] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 106, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0210] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 107, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0211] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 108, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0212] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 109, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0213] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 110, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0214] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 111, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0215] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 112, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0216] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 113, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0217] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 114, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0218] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 115, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0219] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 116, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0220] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 97, HC contact region 2 of SEQ ID NO: 138, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0221] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 102, HC contact region 2 of SEQ ID NO: 139, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0222] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 132, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0223] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 133, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0224] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 134, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0225] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0226] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 99, HC contact region 2 of SEQ ID NO: 140, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0227] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 95, HC contact region 2 of SEQ ID NO: 141, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0228] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 96, HC contact region 2 of SEQ ID NO: 142, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0229] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 152, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0230] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 153, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0231] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 164, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0232] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 169, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0233] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 171, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0234] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 172, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0235] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 174, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0236] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 176, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0237] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 181, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0238] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 182, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0239] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 186, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0240] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 188, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0241] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 191, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0242] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 194, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0243] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 195, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0244] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 198, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0245] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 200, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0246] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 203, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0247] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 204, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0248] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 205, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0249] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 206, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0250] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 212, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0251] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 215, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0252] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 218, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0253] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 220, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0254] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 227, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0255] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 228, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0256] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 229, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0257] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 230, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0258] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 231, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0259] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 232, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0260] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 237, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0261] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 97, HC contact region 2 of SEQ ID NO: 138, CDR3 of SEQ ID NO: 134, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0262] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 96, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0263] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 96, HC contact region 2 of SEQ ID NO: 142, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0264] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 95, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0265] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 99, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0266] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 241, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0267] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 154, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0268] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 155, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0269] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 156, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0270] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 157, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0271] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 158, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0272] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 159, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0273] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 160, HC contact region 2 of SEQ ID NO: 107, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0274] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 161, HC contact region 2 of SEQ ID NO: 109, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0275] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 162, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0276] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 163, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0277] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 165, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0278] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 166, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0279] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 167, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0280] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 168, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0281] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 170, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0282] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 173, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0283] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 175, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0284] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 177, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0285] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 178, HC contact region 2 of SEQ ID NO: 109, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0286] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 179, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0287] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 180, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0288] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 183, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0289] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 184, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0290] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 185, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0291] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 187, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0292] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 189, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0293] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 190, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0294] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 192, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0295] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 193, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0296] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 196, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0297] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 197, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0298] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 199, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0299] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 201, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0300] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 202, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0301] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 207, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0302] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 208, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0303] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contactregion 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 209, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0304] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 210, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0305] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 211, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0306] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 213, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0307] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 214, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0308] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 216, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0309] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 217, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0310] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 219, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0311] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 221, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0312] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 222, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0313] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 223, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0314] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 224, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0315] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 225, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0316] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 226, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0317] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 115, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0318] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 233, HC contact region 2 of SEQ ID NO: 108, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0319] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 102, HC contact region 2 of SEQ ID NO: 234, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0320] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 102, HC contactregion 2 of SEQ ID NO: 139, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0321] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 97, HC contact region 2 of SEQ ID NO: 138, CDR3 of SEQ ID NO: 135, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0322] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 97, HC contact region 2 of SEQ ID NO: 138, CDR3 of SEQ ID NO: 133, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0323] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 102, HC contact region 2 of SEQ ID NO: 109, CDR3 of SEQ ID NO: 3, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0324] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 240, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0325] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising HC contact region 1 of SEQ ID NO: 91, HC contact region 2 of SEQ ID NO: 105, CDR3 of SEQ ID NO: 242, and optionally light chain CDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

[0326] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof (e.g., 1101, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, or 131314 or a variant thereof) which has a light chain variable region (VL) having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof (or a variant thereof) which has the light chain variable region (VL) of SEQ ID NO: 13.

[0327] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof, having the heavy chain contact regions, or CDRs, or the VH of any one of antibodies 1 to 95, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303,1304, 1306, 1313, 131307, 131311, or 131314, which has a light chain variable region (VL) having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, provided herein is an anti-RSV antibody or an antigen-binding fragment thereof having the heavy chain contact regions, or CDRs, or the VH of any one of antibodies I to 95, 1103, 1105, 1106, 1107, 1109, 1110, 1111, 1112, 1113, 1115, 1116, 1117, 1201, 1202, 1203, 1204, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1215, 1216, 1303, 1304, 1306, 1313, 131307, 131311, or 131314, which has the light chain variable region (VL) of SEQ ID NO: 13.

[0328] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 16, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 16 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0329] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 19, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 19 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0330] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 22, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 22 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0331] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 25, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 25 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0332] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 28, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 28 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acidchanges are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0333] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 34, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 34 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0334] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 37, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 37 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0335] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 40, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 40 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0336] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 43, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 43 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0337] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 46, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 46 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewerthan 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0338] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 49, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 49 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0339] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 52, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 52 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0340] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 55, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 55 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In someembodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0341] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 58, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 58 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0342] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 61, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 61 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0343] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 64, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 64 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0344] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 67, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 67 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0345] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 70, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 70 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acidchanges are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0346] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 73, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 73 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0347] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 76, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 76 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0348] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 79, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 79 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0349] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 82, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 82 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0350] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 85, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 85 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewerthan 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0351] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 88, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 88 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0352] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:143, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 143 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0353] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:144, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 144 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In someembodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0354] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:145, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 145 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0355] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:146, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 146 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0356] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:147, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 147 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0357] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:148, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 148 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0358] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:149, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 149 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acidchanges are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0359] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:150, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 150 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0360] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:151, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 151 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0361] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO: 243, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 243 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0362] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:244, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 244 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0363] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:245, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 245 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewerthan 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0364] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:246, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 246 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0365] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:247, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 247 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0366] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:248, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 248 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In someembodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0367] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:249, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 249 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0368] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:250, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 250 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0369] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:251, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 251 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0370] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:252, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 252 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0371] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:253, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 253 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acidchanges are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0372] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:254, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 254 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0373] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:255, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 255 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0374] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:256, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 256 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In some embodiments, the VL of SEQ ID NO: 13 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VL. In some embodiments, the amino acid changes are in equal to or less than 25%, 20%, 15%, 10%, 5%, 3%, 2% or 1% of the amino acid sequence of the VH or VL framework regions (e.g., the framework regions of the VH outside the HC contact regions). In some embodiments, the amino acid changes are in fewer than 30, 25, 20, 15, 10, 5, 4, 3, or 2 amino acids of the VH or VL framework regions (e.g., the regions outside of the HC contact regions).

[0375] In some embodiments, provided herein is an anti-RSV antibody or an antigenbinding fragment thereof comprising the heavy chain variable region (VH) of SEQ ID NO:257, and optionally a VL having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. In some embodiments, the VH of SEQ ID NO: 257 can be modified to have amino acid changes (e.g., substitutions) in the framework region(s) of the VH (e.g., the framework regions outside the HC contact regions). In so...

Claims

What is claimed is:

1. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 150, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91, or an amino acid sequence that differs from SEQ ID NO: 91 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): E30Q, E30G, D31G, 133 V, I34V, and N35S, in any combination;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105, or an amino acid sequence that differs from SEQ ID NO: 105 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): 15 IM, I52V, L55F, T57A, H59Y, G61A, P62S, G66A, and G66R, in any combination ; and(iii) a heavy chain contact region 3 comprising ATETALVVTGTYFLHYFDN (SEQ ID NO: 135); and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

2. The antibody or antigen-binding fragment of claim 1, wherein the heavy chain contact region 2 comprises SEQ ID NO: 105, or an amino acid sequence that differs from SEQ ID NO: 105 by having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): I52V, L55F, G61A, P62S, G66A, and G66R, in any combination.

3. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 150, and comprising(i) a heavy chain contact region 1 comprising an amino acid sequence selected from SEQ ID NOs: 91, 95, 96, and 99;(ii) a heavy chain contact region 2 comprising an amino acid sequence selected from SEQ ID NOs: 105, 141, and 142; and(iii) a heavy chain contact region 3 comprising ATETALVVTGTYFLHYFDN (SEQ ID NO: 135); and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

4. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 150, 148, 326, 327, 332, 151, 332, 333, and 334, or contact regions thereof; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

5. The antibody or antigen -binding fragment of any one of claims 1-3, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 150, 148, 332, 151, 333, and 334, or contact regions thereof.

6. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the heavy chain contact region 1 comprises SEQ ID NO: 95, and the heavy chain contact region 2 comprises SEQ ID NO: 141.

7. The antibody or antigen-binding fragment of claim 6, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 150, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

8. The antibody or antigen -binding fragment of any one of claims 1-3, wherein the heavy chain contact region 1 comprises SEQ ID NO: 91, and the heavy chain contact region 2 comprises SEQ ID NO: 105.

9. The antibody or antigen-binding fragment of claim 8, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 148, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

10. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the heavy chain contact region 1 comprises SEQ ID NO: 96, and the heavy chain contact region 2 comprises SEQ ID NO: 142.

11. The antibody or antigen -binding fragment of claim 10, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 151, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

12. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the heavy chain contact region 1 comprises SEQ ID NO: 95, the heavy chain contact region 2 comprises SEQ ID NO: 105.

13. The antibody or antigen -binding fragment of claim 12, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 333, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:13.

14. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the heavy chain contact region 1 comprises SEQ ID NO: 99, and the heavy chain contact region 2 comprises SEQ ID NO: 105.

15. The antibody or antigen -binding fragment of claim 14, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 334, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

16. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 146, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having a substitution at position Pl 10 and a substitution at position Nil 5 (relative to SEQ ID NO: 10 numbering), wherein the substitution at position Pl 10 is selected from: P110S, P110A, P110L and P110I, and the substitution at position N115 is selected from: N115D, N115R, N115K, N115S, N115L, N115E, N115V, N115Q and Nil 51, and optionally further having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): A101 V, V103A, V103I, V104I, E106Q, and L109I, in any combination; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

17. The antibody or antigen-binding fragment of claim 16, wherein the substitution at position N115 is selected from N115D, N115R, N115K and N115 S.

18. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 146, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 133, 134, 152, 169, 172, 176, 181, 182, 186, 203, 204, 205, 212, and 215; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

19. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 146, 147, 243, 246-250, 256, 260, 263, 267, 268, 272, 273, 277, 287, 294-296, 303, 306, 312, 313, 317, 329, and 330, or contact regions thereof; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

20. The antibody or antigen-binding fragment of any one of claims 16-18, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 146, 147, 243, 260, 263, 267, 272, 273, 277, 294-296, 303, 306, and 330, or contact regions thereof.

21. The antibody or antigen-binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 133.

22. The antibody or antigen-binding fragment of claim 21, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 146, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

23. The antibody or antigen -binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 172.

24. The antibody or antigen-binding fragment of claim 23, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 263, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

25. The antibody or antigen -binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 181.

26. The antibody or antigen-binding fragment of claim 25, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 272, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

27. The antibody or antigen-binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 182.

28. The antibody or antigen -binding fragment of claim 27, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 273, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

29. The antibody or antigen-binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 186.

30. The antibody or antigen-binding fragment of claim 29, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 277, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

31. The antibody or antigen -binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 203.

32. The antibody or antigen-binding fragment of claim 31, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 294, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

33. The antibody or antigen -binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 212.

34. The antibody or antigen-binding fragment of claim 33, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 303, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

35. The antibody or antigen-binding fragment of any one of claims 16-18, wherein the heavy chain contact region 3 comprises SEQ ID NO: 134.

36. The antibody or antigen-binding fragment of claim 35, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 147, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

37. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising or an amino acid sequence that differs from SEQ ID NO: 3 by having substitutions at the following positions (relative to SEQ ID NO: 10 numbering):(a) a substitution at position Al 01 selected from A101G, A101T, A101I, and A101V;(b) at least two, three or more substitutions selected from: T100I, T100D, TIOOS, T100Y, L102V, L102I, V103L, V103I, V103A, E106D, T107Q, L109F, L109I, L109A, P110A, P110G, F113L, F113Y, N115Q, N115K, and Nil 5R, in any combination; and(c) optionally, a substitution VI 041 and / or E99Q; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NON, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

38. The antibody or antigen-binding fragment of claim 37, wherein the substitution at position A101 is A101G or A101I, and wherein the two, three or more substitutions in the heavy chain contact region 3 are selected from: TIOOS, L102V, V103L, V104I, L109I, P110A, F113Y, F113L, N115K, and N115Q.

39. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 132, 152, 153,188, 194, 198, 203, 212, 218, 220, and 227; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

40. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 145, 243, 244, 279, 283, 284, 285, 289, 290, 294, 302, 303, 304, 305, 307, 308, 309-316, and 318, or contact regions thereof; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

41. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 145, 243, 244, 279, 285, 289, 294, 303, 309, 311, and 318, or contact regions thereof.

42. The antibody or antigen-binding fragment of any one of claims 16-18 and 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 152.

43. The antibody or antigen-binding fragment of claim 42, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 243, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

44. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 194.

45. The antibody or antigen -binding fragment of claim 44, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 285, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

46. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 198.

47. The antibody or antigen-binding fragment of claim 46, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 289, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

48. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 218.

49. The antibody or antigen-binding fragment of claim 48, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 309, and optionallywherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

50. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 227.

51. The antibody or antigen-binding fragment of claim 50, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 318, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

52. The antibody or antigen-binding fragment of any one of claims 37-39, wherein the heavy chain contact region 3 comprises SEQ ID NO: 132.

53. The antibody or antigen-binding fragment of claim 52, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 145, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

54. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having amino acid substitutions at two or three of the positions selected from LI 02, Nil 5 and VI 04 (relative to SEQ ID NO: 10 numbering), wherein the substitution at L102 is L102I or L102V, the substitution at N115 is N115R, N115H, N115K or N115Q, the substitution at VI 04 is V104A, VI 041, or V104L; and optionally, further comprising one or more amino acid substitutions selected from: E99D, T100D, A101G, V103L, V103I, L109A, L109V, L109I, P110A, P110I, F113W and F113L; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NON, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

55. The antibody or antigen-binding fragment of claim 54, wherein the substitution at position VI 04 is VI 041 or V104A, and the substitution at position Nil 5 is N115Q, N115K or N115R, and optionally, further comprising one or more amino acid substitutions selected from: A101G, L109I, L109A, P110A, and F113L.

56. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 243, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 152, 164, 169, 171, 172, 174, 181, 182, 195, 227, 228, 231, and 232; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

57. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 243, 245, 254, 255, 257, 258, 260, 261, 262, 263, 264, 265, 266, 271, 272, 273, 276, 278, 286, 287, 292, 302, 305, 310, 318, 319, 322, and 323, or contact regions thereof; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

58. The antibody or antigen-binding fragment of any one of claims 54-56, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 243, 255, 260, 262, 263, 265, 272, 273, 286, 318, 319, 322, and 323, or contact regions thereof.

59. The antibody or antigen-binding fragment of any one of claims 54-56, wherein the heavy chain contact region 3 comprises SEQ ID NO: 164.

60. The antibody or antigen-binding fragment of claim 59, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 255, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

61. The antibody or antigen-binding fragment of any one of claims 54-56, wherein the heavy chain contact region 3 comprises SEQ ID NO: 174.

62. The antibody or antigen-binding fragment of claim 61, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 265, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

63. The antibody or antigen-binding fragment of any one of claims 54-56, wherein the heavy chain contact region 3 comprises SEQ ID NO: 228.

64. The antibody or antigen-binding fragment of claim 63, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 319, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

65. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 297, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence that differs from SEQ ID NO: 3 by having a substitution at position E106 and a substitution at position Y112 (relative to SEQ ID NO: 10 numbering), wherein the substitution at position E106 is selected from: E106R, E106S and E106I, and the substitution at position Y112 is selected from: Y112S, Y112G, Y112A, and Y112D, and optionally further having one or more amino acid substitutions selected from (relative to SEQ ID NO: 10 numbering): Y108I, Y108S, S105T, and H111S, in any combination; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

66. The antibody or antigen-binding fragment of claim 65, wherein the substitution at position E106 is E106R, E106I or E106S, and the substitution at position Y112 is Y112S, Y112G or Y112D, and optionally, further comprising one or more amino acid substitutions selected from: S105T, Y108I, and Y108S.

67. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 297, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 200, 206, 237, and 241; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) toSEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

68. The antibody or antigen-binding fragment of any one of claims 65-67, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 291, 297, 328, and 336, or contact regions thereof.

69. The antibody or antigen-binding fragment of any one of claims 65-67, wherein the heavy chain contact region 3 comprises SEQ ID NO: 200.

70. The antibody or antigen-binding fragment of claim 69, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 291, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

71. The antibody or antigen-binding fragment of any one of claims 65-67, wherein the heavy chain contact region 3 comprises SEQ ID NO: 206.

72. The antibody or antigen-binding fragment of claim 71, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 297, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

73. The antibody or antigen-binding fragment of any one of claims 65-67, wherein the heavy chain contact region 3 comprises SEQ ID NO: 241.

74. The antibody or antigen-binding fragment of claim 73, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 336, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

75. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 320, and comprising:(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105; and(iii) a heavy chain contact region 3 comprising or an amino acid sequence that differs from SEQ ID NO: 3 by having amino acid substitutions at the following positions (relative to SEQ ID NO: 10 numbering):(c) a substitution E99D;(d) at least two, three or more substitutions selected from: T100Y, L102V,LI 021, V103L, VI 031, V104A, V104L, LI 09V, LI 091, N115K, N115R, in any combination; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO:4, a light chain CDR2 comprising SEQ ID NO:5, and a light chain CDR3 comprising SEQ ID NO:6.

76. The antibody or antigen-binding fragment of claim 75, wherein the at least two, three or more substitutions are selected from: T100Y, L102V, V103L, L104A, and L104L.

77. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 320, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105;(iii) a heavy chain contact region 3 comprising an amino acid sequence selected from SEQ ID NOs: 228, 229, 230, 231, and 232; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

78. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 319, 320, 321, 322, and 323, or contact regions thereof.

79. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain contact region 3 comprises SEQ ID NO: 228.

80. The antibody or antigen-binding fragment of claim 79, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 319, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

81. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain contact region 3 comprises SEQ ID NO: 229.

82. The antibody or antigen-binding fragment of claim 81, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 320, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

83. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain contact region 3 comprises SEQ ID NO: 230.

84. The antibody or antigen-binding fragment of claim 83, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 321, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

85. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain contact region 3 comprises SEQ ID NO: 231.86 The antibody or antigen-binding fragment of claim 85, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 322, and optionallywherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

87. The antibody or antigen-binding fragment of any one of claims 75-77, wherein the heavy chain contact region 3 comprises SEQ ID NO: 232.

88. The antibody or antigen-binding fragment of claim 87, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 323, and optionally wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

89. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 282, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 91;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 105;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 191; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

90. The antibody or antigen-binding fragment of claim 89, wherein the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 282.

91. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 144, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 102;(ii) a heavy chain contact region 2 comprising SEQ ID NO: 139;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 3; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

92. The antibody or antigen-binding fragment of claim 91, wherein the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 144.

93. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) and comprises:(1) a heavy chain variable domain having at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 10 or SEQ ID NO: 282, and comprising(i) a heavy chain contact region 1 comprising SEQ ID NO: 102;(ii) a heavy chain contact region 2 comprising an amino acid sequence that differs from SEQ ID NO: 105 in having an amino acid substitution at position G50 (relative to SEQ ID NO: 10 numbering), wherein the substitution is G50C or G50S;(iii) a heavy chain contact region 3 comprising an amino acid sequence of SEQ ID NO: 3; and(2) optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

94. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising contact regions 1, 2, and 3 of an antibody selected from: SEQ ID NOs: 25, 28, 143, 144, 145, 146, 147, 148, 150, 151, 243-337; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

95. An antibody or antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) comprising a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NOs: 25, 28, 143, 144, 145, 146, 147, 148, 150, 151, 243- 337; and optionally, a light chain variable domain having at least 75%, 80%, 85%, 90%, 95%, or 100% amino acid sequence identity (optionally, at least 85% amino acid sequence identity) to SEQ ID NO: 13, and comprising a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6.

96. The antibody or antigen-binding fragment of any one of claims 1-95, wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13.

97. The antibody or antigen-binding fragment of any one of claims 1-96, which is a monoclonal antibody.

98. The antibody or antigen-binding fragment of any one of claims 1-97, which is a human, humanized, or chimeric antibody.

99. The antibody or antigen-binding fragment of any one of claims 1-96, which is a human monoclonal antibody.

100. The antibody or antigen-binding fragment of any one of claims 1-99, which comprises an IgGl heavy chain constant region.

101. The antibody or antigen -binding fragment of any one of claims 1-100, which comprises a human IgG 1 heavy chain constant region comprising an Fc region comprising substitutions M252Y, S254T, and T256E, or Y at position 252, T at position 254, and E at position 256, wherein the position numbering corresponds to EU numbering.

102. The antibody or antigen-binding fragment of any one of claims 1-101, which comprises kappa light chain constant region.

103. The antibody or antigen-binding fragment of any one of claims 1-102, which is a human recombinant IgGl kappa monoclonal antibody.

104. The antibody or antigen-binding fragment thereof of any one of claims 1-99, which is an antigen-binding fragment, optionally which is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab')2 fragment.

105. The antibody or antigen -binding fragment of any one of claims 1-104, wherein the antibody or antigen-binding fragment thereof is effective at neutralizing RSV subtype A strain and / or RSV subtype B strain.

106. The antibody or antigen-binding fragment of any one of claims 1-105, wherein the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 equal to or less than 50 ng / mL, 40 ng / mL, 30 ng / mL, 25 ng / mL, 20 ng / mL, 15 ng / mL, 10 ng / mL, 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL.

107. The antibody or antigen-binding fragment of any one of claims 1-106, wherein the antibody or antigen-binding fragment thereof is effective at neutralizing RSV (optionally RSV A2) in a cell-based virus neutralization assay with an IC50 at least 1.5X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X lower than the IC50 achieved by 1G7 antibody (an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823) in the same assay.

108. An agent comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is equal to or less than 10 ng / mL, 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL; and(ii) means for increasing half-life of the agent.

109. The agent of claim 108, wherein the IC50 is an average IC50, and / or wherein the IC50 is equal to or less than 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL.

110. An agent comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is at least 1.2X, 1.5X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X better than the IC50 achieved by 1G7 antibody (an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823); and(ii) means for increasing half-life of the agent.

111. The agent of claim 110, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 1.5X better than the IC50 achieved by the 1G7 antibody.

112. The agent of claim 110, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 2X better than the IC50 achieved by the 1G7 antibody.

113. The agent of claim 110, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 3X better than the IC50 achieved by the 1G7 antibody.

114. The agent of claim 110, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 5X better than the IC50 achieved by the 1G7 antibody.

115. The agent of claim 110, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 8X better than the IC50 achieved by the 1G7 antibody.

116. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of any one of claims 1-107 or an agent of any one of claims 108-115.

117. A vector comprising the isolated nucleic acid of claim 116.

118. A host cell comprising the isolated nucleic acid of claim 116 or the vector of claim 117.

119. A pharmaceutical composition, comprising:(i) the antibody or antigen-binding fragment thereof of any one of claims 1-107 or an agent of any one of claims 108-115; and(ii) a pharmaceutically acceptable carrier or excipient.

120. A pharmaceutical composition, comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is equal to or less than 10 ng / mL, 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL,(b) a pharmaceutically acceptable carrier or excipient.

121. The pharmaceutical composition of claim 120, wherein the IC50 is an average IC50, and / or wherein the IC50 is equal to or less than 5 ng / mL, 3 ng / mL, 2 ng / mL, or 1 ng / mL.

122. A pharmaceutical composition, comprising:(a) means for binding and neutralizing RSV subtype A strain and / or RSV subtype B strain, wherein the IC50 for neutralizing RSV is at least 1.2X, 1.5X, 2X, 2.5X, 3X, 3.5X, 4X, 4.5X, 5X, 8X, or 10X better than the IC50 achieved by 1G7 antibody (an antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region of the amino acid sequence of SEQ ID NO: 13, and / or an antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 1822 and a light chain of the amino acid sequence of SEQ ID NO: 1823); and(b) a pharmaceutically acceptable carrier or excipient.

123. The pharmaceutical composition of claim 122, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 1.5X better than the IC50 achieved by the 1G7 antibody.

124. The pharmaceutical composition of claim 122, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 2X better than the IC50 achieved by the 1G7 antibody.

125. The pharmaceutical composition of claim 122, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 3X better than the IC50 achieved by the 1G7 antibody.

126. The pharmaceutical composition of claim 122, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 5X better than the IC50 achieved by the 1G7 antibody.

127. The pharmaceutical composition of claim 122, wherein the IC50 is an average IC50 or an IC50 measured in the same assay, and / or wherein the IC50 is at least 8X better than the IC50 achieved by the 1G7 antibody.

128. The pharmaceutical composition of any one of claims 119-127, wherein the pharmaceutical composition is formulated for parenteral administration, optionally formulated for intramuscular injection.

129. A method of preventing Respiratory Syncytial Virus (RSV) infection in a subject, wherein the method comprises administering to the subject the antibody or antigen-binding fragment thereof of any one of claims 1-107, an agent of any one of claims 108-115, or the pharmaceutical composition of any one of claims 119-128.

130. A method of preventing Respiratory Syncytial Virus (RSV) disease in a subject, wherein the method comprises administering to the subject the antibody or antigen-binding fragment thereof of any one of claims 1-107, an agent of any one of claims 108-115, or the pharmaceutical composition of any one of claims 119-128.

131. A method of treating Respiratory Syncytial Virus (RSV) disease in a subject, wherein the method comprises administering to the subject the antibody or antigen-binding fragment thereof of any one of claims 1-107, an agent of any one of claims 108-115, or the pharmaceutical composition of any one of claims 119-128.

132. The method of claim 130 or 131, wherein the RSV disease is RSV lower respiratory tract disease.

133. The method of any one of claims 129-132, wherein the subject is a human subject.

134. The method of claim 133, wherein the human subject is at an increased risk of RSV infection or RSV disease.

135. The method of claim 133 or 134, wherein the human subject is an infant born prematurely, a child under 24 months of age, an adult over 65 years of age, a subject with a chronic lung disease, a subject with a chronic heart disease, or an immunocompromised subject.

136. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered parenterally.

137. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered intramuscularly.

138. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of less than 10 mg / kg, or equal to or less than 7.5 mg / kg.

139. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of equal to or less than 5 mg / kg, 4 mg / kg, 3 mg / kg, 2.5 mg / kg, 2 mg / kg, or 1 mg / kg.

140. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof or the agent is administered intramuscularly in a dose of equal to or less than 5 mg, 10 mg, 20 mg, 25 mg, 50 mg, 75 mg, or 100 mg (optionally, 5 mg to 25 mg for children less than 5 kg, and 10 mg to 50 mg for children 5 kg or more).

141. The method of any one of claims 129-135, wherein the antibody or antigen-binding fragment thereof, the agent or the pharmaceutical composition is administered subcutaneously.

142. A method of manufacturing an anti-Respiratory Syncytial Virus (RSV) antibody or antigen-binding fragment thereof of any one of claims 1-107, wherein the method comprises culturing the host cell of claim 118 under conditions suitable for expressing the antibody or antigen-binding fragment thereof, followed by recovering the antibody or antigen-binding fragment thereof from the host cell, and optionally followed by purifying the antibody or antigen-binding fragment thereof.

143. A kit compri sing : a) the antibody or antigen-binding fragment thereof according to any one of claims 1- 107, the agent of any one of claims 108-115, or the pharmaceutical composition of any one of claims 119-128; and b) instructions for administration of the antibody or antigen-binding fragment thereof to prevent or treat Respiratory Syncytial Virus (RSV) infection or RSV disease.